MX2021013347A - Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina. - Google Patents

Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.

Info

Publication number
MX2021013347A
MX2021013347A MX2021013347A MX2021013347A MX2021013347A MX 2021013347 A MX2021013347 A MX 2021013347A MX 2021013347 A MX2021013347 A MX 2021013347A MX 2021013347 A MX2021013347 A MX 2021013347A MX 2021013347 A MX2021013347 A MX 2021013347A
Authority
MX
Mexico
Prior art keywords
associated pain
diaminopyrimidine compound
treating endometriosis
compound
treating
Prior art date
Application number
MX2021013347A
Other languages
English (en)
Inventor
Jin Wang
Zhou Lan
Yanping Zhao
Hongjun Wang
Huai Huang
Liying Zhou
Yanan Liu
Yuanyuan Jiang
Huining Liang
Ran An
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of MX2021013347A publication Critical patent/MX2021013347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(ver Fórmula) Método para tratar, resistir y aliviar el dolor asociado con endometriosis, relacionado con el campo de la medicina biológica, que comprende administrar, a una persona que lo necesite, una cantidad terapéuticamente eficaz de un compuesto de diaminopirimidina de fórmula (I) o una sal, un éster, un estereoisómero, un polimorfo, un solvato, un N-óxido, un compuesto marcado isotópicamente, un metabolito o un profármaco del mismo farmacéuticamente aceptable.
MX2021013347A 2019-04-30 2020-04-29 Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina. MX2021013347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (1)

Publication Number Publication Date
MX2021013347A true MX2021013347A (es) 2022-01-24

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013347A MX2021013347A (es) 2019-04-30 2020-04-29 Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.

Country Status (12)

Country Link
US (1) US20220249478A1 (es)
EP (1) EP3960178A4 (es)
JP (1) JP2022531570A (es)
KR (1) KR20220008286A (es)
CN (1) CN114007620B (es)
AU (1) AU2020266947A1 (es)
BR (1) BR112021021838A8 (es)
CA (1) CA3138238A1 (es)
MX (1) MX2021013347A (es)
SG (1) SG11202111960PA (es)
TW (1) TWI737285B (es)
WO (1) WO2020221277A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018361276B2 (en) * 2017-11-01 2022-11-24 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
MA43821A (fr) * 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc Pyrimidines et variantes de celles-ci, et leurs utilisations
US10662162B2 (en) * 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2018361276B2 (en) * 2017-11-01 2022-11-24 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

Also Published As

Publication number Publication date
SG11202111960PA (en) 2021-12-30
CN114007620B (zh) 2024-08-06
EP3960178A4 (en) 2023-01-25
KR20220008286A (ko) 2022-01-20
TW202106303A (zh) 2021-02-16
BR112021021838A8 (pt) 2023-02-28
AU2020266947A1 (en) 2021-12-16
TWI737285B (zh) 2021-08-21
EP3960178A1 (en) 2022-03-02
WO2020221277A1 (zh) 2020-11-05
BR112021021838A2 (pt) 2022-01-04
CN114007620A (zh) 2022-02-01
CA3138238A1 (en) 2020-11-05
US20220249478A1 (en) 2022-08-11
JP2022531570A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
PH12018501390A1 (en) Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
WO2011126910A3 (en) Compositions and methods for the treatment of somatosensory disorders
MX2013012588A (es) Inhibidores de cinasa.
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
WO2013085849A3 (en) Sulfate esters of noribogaine
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
ZA202311035B (en) Phosphonyl derivative, and composition and pharmaceutical application thereof
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
MX2024000807A (es) Inhibidor de aak1 y uso de este.
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.